HC Wainwright Issues Pessimistic Estimate for TRVI Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Stock analysts at HC Wainwright cut their FY2026 earnings estimates for shares of Trevi Therapeutics in a report released on Tuesday, August 11th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.48) per share for the year, down from their previous forecast of ($0.47). HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.71) EPS and FY2029 earnings at ($0.15) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11).

A number of other research firms have also recently issued reports on TRVI. Oppenheimer raised their price objective on Trevi Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $30.00 target price on Trevi Therapeutics in a report on Friday, May 8th. Cantor Fitzgerald increased their price target on Trevi Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. Finally, Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $26.75.

Trevi Therapeutics Stock Down 0.4%

Shares of NASDAQ TRVI opened at $17.73 on Thursday. The business’s 50 day moving average price is $17.22 and its two-hundred day moving average price is $14.18. The company has a market cap of $2.53 billion, a PE ratio of -52.15 and a beta of 1.03. Trevi Therapeutics has a twelve month low of $6.93 and a twelve month high of $20.22.

Institutional Investors Weigh In On Trevi Therapeutics

Several hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its holdings in shares of Trevi Therapeutics by 20.4% during the first quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock worth $174,000 after acquiring an additional 4,688 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Trevi Therapeutics by 31.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock worth $278,000 after purchasing an additional 10,445 shares during the period. Millennium Management LLC lifted its holdings in Trevi Therapeutics by 356.3% during the 1st quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock worth $5,178,000 after purchasing an additional 642,830 shares during the last quarter. Strs Ohio acquired a new stake in Trevi Therapeutics during the 1st quarter worth approximately $52,000. Finally, Creative Planning lifted its holdings in Trevi Therapeutics by 17.5% during the 2nd quarter. Creative Planning now owns 20,247 shares of the company’s stock worth $111,000 after purchasing an additional 3,016 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.